Key points from article :
Biobeat, an Israeli medical technology company, has secured $50 million (£37 million) in funding to expand the use of its wearable blood pressure monitoring technology in the United States. The investment will help the company commercialise a small chest-worn patch that can measure blood pressure continuously for 24 hours without the inflatable cuffs traditionally used in clinical monitoring.
High blood pressure affects more than 100 million people in the US and is a major risk factor for heart disease, stroke and other age-related conditions. Conventional ambulatory blood pressure monitors rely on cuffs that repeatedly inflate throughout the day and night, often disturbing sleep and leading some patients to remove the device before monitoring is complete. Biobeat's patch aims to solve this problem by collecting data continuously while allowing users to go about their normal activities.
The company says its device can improve patient comfort and increase compliance, potentially providing doctors with more complete and reliable blood pressure data. The latest funding round was led by healthcare investors Ally Bridge Group, OrbiMed Advisors and Elevage Medical, and will support wider adoption of the technology across the US healthcare system.
Supporters believe wearable, cuffless monitoring could make it easier to detect and manage hypertension before it leads to serious health problems. While further evidence and adoption will be needed to establish the technology as a new standard of care, Biobeat's funding reflects growing interest in wearable devices that bring medical monitoring out of the clinic and into everyday life.
